Gain Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
GANX$1.09+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · 2023 · 2022 | ||||||
| Net loss | | $(22,267,520) | | $(17,590,738) | ||
| Unrealized gain / (loss) on available-for-sale marketable securities | | | 89,304 | | | (94,279) |
| Defined benefit pension plan | | | (127,601) | | | 227,131 |
| Foreign currency translation | | 249,911 | | (6,580) | ||
| Other comprehensive income | | $211,614 | | $126,272 | ||
| Comprehensive loss | | $(22,055,906) | | $(17,464,466) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.